Additionally, in a first-in-human phase 0 study, we previously reported that the indium-111 (111In)–labeled anti-KLK2 monoclonal antibody, [111In]-DOTA-h11B6, demonstrated tumor localization by selectively targeting mCRPC lesions with nominal uptake in healthy organs (31). This evidence concerns the gene KLK2 and neoplasm.